Middle East And Africa Myasthenia Gravis Treatment Market By Drug class (Monoclonal antibodies, Intravenous immunoglobulin, Others), By Age group (Below 55 years, Above 55 years), By Distribution channel (Hospital pharmacies, Drug store and retail pharmacies, Online providers): Opportunity Analysis and Industry Forecast, 2023-2032

Middle East And Africa Myasthenia Gravis Treatment Market

The Middle East and Africa myasthenia gravis treatment market is anticipated to witness significant growth in the future due to rise in prevalence of the disease. Myasthenia Gravis (MG) is a chronic autoimmune disorder, characterized by fatigued skeletal muscles, resulting in partial or complete paralysis.

The Middle East and Africa myasthenia gravis treatment market is driven by various factors, including rise in awareness among individuals regarding the diseases, surge in disposable income of individuals, increase in efforts by government & key players to support individuals suffering from the disease, and boost in number of medical practitioners & healthcare professionals. The Governments of Middle East and Africa are taking initiatives to increase awareness among citizens regarding myasthenia gravis & various treatments available for it. This is anticipated to augment the market growth during the forecast period.

However, the major restraints of the Middle East and Africa myasthenia gravis treatment market are high costs associated with its medications, limited availability of certain medicines, and their side effects. On the contrary, rise in investments in R&D activities by governments and leading market players is projected to boost the market in the upcoming years. In addition, continuous advancements in the healthcare sector, which captures and compiles the data regarding prevalence of the disease, are projected to provide various lucrative opportunities to key market players in the Middle East and Africa. Furthermore, the Middle East and Africa myasthenia gravis treatment market is anticipated to augment in the future owing to developments in healthcare infrastructure and increase in access to healthcare among the population.

The Middle East and Africa myasthenia gravis treatment market is segmented by drug class, age group, and distribution channel. On the basis of drug class, the market is divided into monoclonal antibodies, intravenous immunoglobulin, and others. Depending on age group, the market is bifurcated into below 55 years and above 55 years. As per distribution channel, the market is categorized into hospital pharmacies, drug store & retail pharmacies, and online providers.

Governments of the Middle East and Africa are expected to play considerable role in the development of the market. They are working to increase investments in R&D and boost the occurrence of clinical trials to develop cost-effective yet potent treatment for myasthenia gravis. In addition, key players in the market aim to tap collaboration opportunities and expand their geographical reach. Furthermore, the market players are striving to garner high market share and gain one-upmanship in the market.

Novartis AG, AbbVie Inc., Biogen, AstraZeneca, GlaxoSmithKline PLC, Hoffmann-La Roche Ltd., Merck & Co., Inc., CSL Behring LLC, Baxter International, and Bristol-Myers Squibb Company are some of the key players operating in the Middle East and Africa myasthenia gravis treatment market.

Key Benefits For Stakeholders

Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.

Analyze the key strategies adopted by major market players in Middle East and Africa Myasthenia Gravis Treatment Market.

Assess and rank the top factors that are expected to affect the growth of Middle East and Africa Myasthenia Gravis Treatment Market.

Top Player positioning provides a clear understanding of the present position of market players.

Detailed analysis of the Middle East and Africa Myasthenia Gravis Treatment Market segmentation assists to determine the prevailing market opportunities.

Identify key investment pockets for various offerings in the market.

Additional benefits you will get with this purchase are:

● Quarterly Update and* (only available with a corporate license, on listed price)

● 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.

● Free Upcoming Version on the Purchase of Five and Enterprise User License.

● 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)

● 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)

● Free data Pack on the Five and Enterprise User License. (Excel version of the report)

● Free Updated report if the report is 6-12 months old or older.

● 24-hour priority response*

● Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

● Product Benchmarking / Product specification and applications

○ Bristol-Myers Squibb Compan

Scope of Middle East And Africa Myasthenia Gravis Treatment Market Report

1.1. Report Description

1.2. Key Market Segments

1.3. Key Benefits to the Stakeholders

1.4. Research Methodology

1.4.1. Primary Research

1.4.2. Secondary Research

1.4.3. Analyst Tools and Models

2.1. CXO Perspective

3.1. Market Definition and Scope

3.2. Key Findings

3.2.1. Top Impacting Factors

3.2.2. Top Investment Pockets

3.3. Porter’s Five Forces Analysis

3.4. Market Dynamics

3.4.1. Drivers

3.4.2. Restraints

3.4.3. Opportunities

3.5. COVID-19 Impact Analysis on the market

4.1. Overview

4.1.1. Market Size and Forecast, By Drug class

4.2. Monoclonal antibodies

4.3. Intravenous immunoglobulin

4.4. Others

5.1. Overview

5.1.1. Market Size and Forecast, By Age group

5.2. Below 55 years

5.3. Above 55 years

6.1. Overview

6.1.1. Market Size and Forecast, By Distribution channel

6.2. Hospital pharmacies

6.3. Drug store and retail pharmacies

6.4. Online providers

7.1. Introduction

7.2. Top winning strategies

7.3. Product Mapping of Top 10 Player

7.4. Competitive Dashboard

7.5. Competitive Heatmap

7.6. Top player positioning, 2022

8.1. Novartis AG

8.1.1. Company overview

8.1.2. Key Executives

8.1.3. Company snapshot

8.1.4. Operating business segments

8.1.5. Product portfolio

8.1.6. Business performance

8.1.7. Key strategic moves and developments

8.2. AbbVie Inc.

8.2.1. Company overview

8.2.2. Key Executives

8.2.3. Company snapshot

8.2.4. Operating business segments

8.2.5. Product portfolio

8.2.6. Business performance

8.2.7. Key strategic moves and developments

8.3. Biogen

8.3.1. Company overview

8.3.2. Key Executives

8.3.3. Company snapshot

8.3.4. Operating business segments

8.3.5. Product portfolio

8.3.6. Business performance

8.3.7. Key strategic moves and developments

8.4. AstraZeneca

8.4.1. Company overview

8.4.2. Key Executives

8.4.3. Company snapshot

8.4.4. Operating business segments

8.4.5. Product portfolio

8.4.6. Business performance

8.4.7. Key strategic moves and developments

8.5. GlaxoSmithKline PLC

8.5.1. Company overview

8.5.2. Key Executives

8.5.3. Company snapshot

8.5.4. Operating business segments

8.5.5. Product portfolio

8.5.6. Business performance

8.5.7. Key strategic moves and developments

8.6. Hoffmann-La Roche Ltd

8.6.1. Company overview

8.6.2. Key Executives

8.6.3. Company snapshot

8.6.4. Operating business segments

8.6.5. Product portfolio

8.6.6. Business performance

8.6.7. Key strategic moves and developments

8.7. Merck & Co., Inc.

8.7.1. Company overview

8.7.2. Key Executives

8.7.3. Company snapshot

8.7.4. Operating business segments

8.7.5. Product portfolio

8.7.6. Business performance

8.7.7. Key strategic moves and developments

8.8. CSL Behring LLC

8.8.1. Company overview

8.8.2. Key Executives

8.8.3. Company snapshot

8.8.4. Operating business segments

8.8.5. Product portfolio

8.8.6. Business performance

8.8.7. Key strategic moves and developments

8.9. Baxter International

8.9.1. Company overview

8.9.2. Key Executives

8.9.3. Company snapshot

8.9.4. Operating business segments

8.9.5. Product portfolio

8.9.6. Business performance

8.9.7. Key strategic moves and developments

8.10. Bristol-Myers Squibb Company

8.10.1. Company overview

8.10.2. Key Executives

8.10.3. Company snapshot

8.10.4. Operating business segments

8.10.5. Product portfolio

8.10.6. Business performance

8.10.7. Key strategic moves and development

LIST OF TABLES

TABLE 01. MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 02. MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)

TABLE 03. MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 04. NOVARTIS AG: KEY EXECUTIVES

TABLE 05. NOVARTIS AG: COMPANY SNAPSHOT

TABLE 06. NOVARTIS AG: OPERATING SEGMENTS

TABLE 07. NOVARTIS AG: PRODUCT PORTFOLIO

TABLE 08. NOVARTIS AG: KEY STRATERGIES

TABLE 09. ABBVIE INC.: KEY EXECUTIVES

TABLE 10. ABBVIE INC.: COMPANY SNAPSHOT

TABLE 11. ABBVIE INC.: OPERATING SEGMENTS

TABLE 12. ABBVIE INC.: PRODUCT PORTFOLIO

TABLE 13. ABBVIE INC.: KEY STRATERGIES

TABLE 14. BIOGEN: KEY EXECUTIVES

TABLE 15. BIOGEN: COMPANY SNAPSHOT

TABLE 16. BIOGEN: OPERATING SEGMENTS

TABLE 17. BIOGEN: PRODUCT PORTFOLIO

TABLE 18. BIOGEN: KEY STRATERGIES

TABLE 19. ASTRAZENECA: KEY EXECUTIVES

TABLE 20. ASTRAZENECA: COMPANY SNAPSHOT

TABLE 21. ASTRAZENECA: OPERATING SEGMENTS

TABLE 22. ASTRAZENECA: PRODUCT PORTFOLIO

TABLE 23. ASTRAZENECA: KEY STRATERGIES

TABLE 24. GLAXOSMITHKLINE PLC: KEY EXECUTIVES

TABLE 25. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT

TABLE 26. GLAXOSMITHKLINE PLC: OPERATING SEGMENTS

TABLE 27. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO

TABLE 28. GLAXOSMITHKLINE PLC: KEY STRATERGIES

TABLE 29. HOFFMANN-LA ROCHE LTD: KEY EXECUTIVES

TABLE 30. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT

TABLE 31. HOFFMANN-LA ROCHE LTD: OPERATING SEGMENTS

TABLE 32. HOFFMANN-LA ROCHE LTD: PRODUCT PORTFOLIO

TABLE 33. HOFFMANN-LA ROCHE LTD: KEY STRATERGIES

TABLE 34. MERCK & CO., INC.: KEY EXECUTIVES

TABLE 35. MERCK & CO., INC.: COMPANY SNAPSHOT

TABLE 36. MERCK & CO., INC.: OPERATING SEGMENTS

TABLE 37. MERCK & CO., INC.: PRODUCT PORTFOLIO

TABLE 38. MERCK & CO., INC.: KEY STRATERGIES

TABLE 39. CSL BEHRING LLC: KEY EXECUTIVES

TABLE 40. CSL BEHRING LLC: COMPANY SNAPSHOT

TABLE 41. CSL BEHRING LLC: OPERATING SEGMENTS

TABLE 42. CSL BEHRING LLC: PRODUCT PORTFOLIO

TABLE 43. CSL BEHRING LLC: KEY STRATERGIES

TABLE 44. BAXTER INTERNATIONAL: KEY EXECUTIVES

TABLE 45. BAXTER INTERNATIONAL: COMPANY SNAPSHOT

TABLE 46. BAXTER INTERNATIONAL: OPERATING SEGMENTS

TABLE 47. BAXTER INTERNATIONAL: PRODUCT PORTFOLIO

TABLE 48. BAXTER INTERNATIONAL: KEY STRATERGIES

TABLE 49. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES

TABLE 50. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT

TABLE 51. BRISTOL-MYERS SQUIBB COMPANY: OPERATING SEGMENTS

TABLE 52. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO

TABLE 53. BRISTOL-MYERS SQUIBB COMPANY: KEY STRATERGIES LIST OF FIGURES

FIGURE 01. MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032

FIGURE 02. SEGMENTATION OF MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032

FIGURE 03. TOP INVESTMENT POCKETS IN MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET (2023-2032)

FIGURE 04. PORTER FIVE-1

FIGURE 05. PORTER FIVE-2

FIGURE 06. PORTER FIVE-3

FIGURE 07. PORTER FIVE-4

FIGURE 08. PORTER FIVE-5

FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET

FIGURE 10. MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET,BY DRUG CLASS, 2022 ($MILLION)

FIGURE 11. MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET,BY AGE GROUP, 2022 ($MILLION)

FIGURE 12. MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET,BY DISTRIBUTION CHANNEL, 2022 ($MILLION)

FIGURE 13. TOP WINNING STRATEGIES, BY YEAR

FIGURE 14. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 15. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 16. PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 17. COMPETITIVE DASHBOARD

FIGURE 18. COMPETITIVE HEATMAP: MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET

FIGURE 19. TOP PLAYER POSITIONING, 2022

FIGURE 20. NOVARTIS AG: NET SALES, 2020-2022* ($MILLION)

FIGURE 21. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 22. NOVARTIS AG: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 23. ABBVIE INC.: NET SALES, 2020-2022* ($MILLION)

FIGURE 24. ABBVIE INC.: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 25. ABBVIE INC.: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 26. BIOGEN: NET SALES, 2020-2022* ($MILLION)

FIGURE 27. BIOGEN: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 28. BIOGEN: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 29. ASTRAZENECA: NET SALES, 2020-2022* ($MILLION)

FIGURE 30. ASTRAZENECA: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 31. ASTRAZENECA: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 32. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022* ($MILLION)

FIGURE 33. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 34. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 35. HOFFMANN-LA ROCHE LTD: NET SALES, 2020-2022* ($MILLION)

FIGURE 36. HOFFMANN-LA ROCHE LTD: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 37. HOFFMANN-LA ROCHE LTD: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 38. MERCK & CO., INC.: NET SALES, 2020-2022* ($MILLION)

FIGURE 39. MERCK & CO., INC.: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 40. MERCK & CO., INC.: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 41. CSL BEHRING LLC: NET SALES, 2020-2022* ($MILLION)

FIGURE 42. CSL BEHRING LLC: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 43. CSL BEHRING LLC: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 44. BAXTER INTERNATIONAL: NET SALES, 2020-2022* ($MILLION)

FIGURE 45. BAXTER INTERNATIONAL: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 46. BAXTER INTERNATIONAL: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 47. BRISTOL-MYERS SQUIBB COMPANY: NET SALES, 2020-2022* ($MILLION)

FIGURE 48. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 49. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE, BY GEOGRAPHY, 2022 (%